

## MedImmune

[View the current MedImmune Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/6860-MedImmune.html)

(<http://www.bioportfolio.com/biocorporate/6860-MedImmune.html>)

### Contact Details:

**One MedImmune Way**

**Gaithersburg**

**MD**

**20878**

**United States of America**

Tel: (301) 398-0000

Fax: 301 527 4200

Email: [infobusdev@medimmune.com](mailto:infobusdev@medimmune.com)

MedImmune Incorporated is a biotechnology company headquartered in Gaithersburg, Maryland with three products on the market and a diverse product development portfolio. MedImmune is focused on using advances in immunology and other biological sciences to develop important new products that address significant medical needs in areas such as infectious diseases, transplantation medicine, autoimmune diseases and cancer. In 1998, the Company launched Synagis (palivizumab) in the United States for preventing respiratory syncytial virus (RSV) in high-risk pediatric patients. Synagis is the first monoclonal antibody approved for an infectious disease and has become an important new pediatric product for the prevention of RSV, the leading cause of pneumonia and bronchiolitis in infants and children. The Company also markets CytoGam (Cytomegalovirus Immune Globulin Intravenous (Human), CMV-IGIV) and RespiGam (Respiratory Syncytial Virus Immune Globulin Intravenous (Human), RSV-IGIV) and has five new product candidates undergoing clinical trials.

### Recent Publications by MedImmune:



- [Avian Influenza H6 Viruses Productively Infect and Cause Illness in Mice and Ferrets.](#)  
*Influenza pandemic preparedness has focused on influenza H5 and H7 subtype...* 22nd August, 2008  
Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD, USA 20892;- J Virol. 2008 Aug 20. ([DOI Direct Link](#))
- [Structural characterization of a human Fc fragment engineered for lack of effector functions.](#)  
*The first three-dimensional structure of a human Fc fragment genetically...* 14th August, 2008  
Department of Antibody Discovery and Protein Engineering, MedImmune Inc.,- Acta Crystallogr D Biol Crystallogr. 2008 Jun;64(Pt 6):700-4. Epub 2008 ([DOI Direct Link](#))
- [IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection.](#)

- Bavarian Nordic is developing IMVAMUNE, which is based on a live...*7th August, 2008  
MedImmune Inc, 297 N Bernardo Ave, Mountain View, CA 94043, USA.- *Curr Opin Mol Ther.* 2008 Aug;10(4):407-17.
- [Respiration consists of two acts: First inspiration, then expiration...](#)  
*Bavarian Nordic is developing IMVAMUNE, which is based on a live...*31st July, 2008  
MedImmune Inc, Clinical Testing Laboratories, 297 North Bernardo Avenue,- *Curr Opin Investig Drugs.* 2008 Aug;9(8):833-5.
  - [Type I interferon: potential therapeutic target for psoriasis?](#)  
*BACKGROUND: Psoriasis is an immune-mediated disease characterized by...*24th July, 2008  
MedImmune, Inc., Gaithersburg, Maryland, United States of America.- *PLoS ONE.* 2008 Jul 16;3(7):e2737. ([DOI Direct Link](#))
  - [Development of a high-throughput Alamar blue assay for the determination of influenza virus infectious dose, serum antiviral neutralization titer and virus capsid phenotype.](#)  
*FluMist is an intranasal influenza live vaccine containing two Influenza A...*18th July, 2008  
MedImmune Vaccines Inc., 297 N. Bernardo Avenue, Mountain View,- *J Virol Methods.* 2008 Jun;150(1-2):63-9. ([DOI Direct Link](#))
  - [The role of IL-21 in regulating B-cell function in health and disease.](#)  
*SUMMARY: Interleukin-21 (IL-21) belongs to a family of cytokines that...*11th July, 2008  
Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal- *Immunol Rev.* 2008 Jun;223:60-86. ([DOI Direct Link](#))
  - [Duration of protection provided by live attenuated influenza vaccine in children.](#)  
*BACKGROUND: Reliable availability of influenza vaccine before October...*5th July, 2008  
MedImmune, One MedImmune Way, Gaithersburg, MD 20878, USA.- *Pediatr Infect Dis J.* 2008 Aug;27(8):744-8. ([DOI Direct Link](#))
  - [Deletion of human metapneumovirus M2-2 increases mutation frequency and attenuates growth in hamsters.](#)  
*BACKGROUND: Human metapneumovirus (hMPV) infection can cause acute lower...*4th July, 2008  
Research Dept, MedImmune, Mountain View, CA 94043, USA.- *Virol J.* 2008 Jun 3;5:69. ([DOI Direct Link](#))
  - [A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets.](#)  
*The appearance of human infections caused by avian influenza A H7 subtype...*1st July, 2008  
Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA;- *Virology.* 2008 Aug 15;378(1):123-32. Epub 2008 Jun 27. ([DOI Direct Link](#))
  - [Analysis of 90 Mb of the potato genome reveals conservation of gene structures and order with tomato but divergence in repetitive sequence composition.](#)  
*BACKGROUND: The Solanaceae family contains a number of important crop...*17th June, 2008  
Department of Plant Biology, Michigan State University, 166 Plant Biology- *BMC Genomics.* 2008 Jun 13;9:286. ([DOI Direct Link](#))
  - [From bench to cageside: Risk assessment for rodent pathogen contamination of cells and biologics.](#)  
*Many newly developed animal models involve the transfer of cells, serum,...*29th May, 2008  
MedImmune, One MedImmune Way, Gaithersburg, MD 20878, USA.- *ILAR J.* 2008;49(3):310-5.
  - [Genomic-based high throughput screening identifies small molecules that differentially inhibit the antiviral and immunomodulatory effects of IFN-alpha.](#)  
*Multiple lines of evidence suggest that inhibition of Type I Interferons,...*14th May, 2008  
Respiratory, Inflammation and Autoimmunity Department, MedImmune Inc.,- *Mol Med.* 2008 Jul-Aug;14(7-8):374-82. ([DOI Direct Link](#))
  - [Strategies for prevention of RSV nosocomial infection.](#)  
*OBJECTIVE: To review the literature on respiratory syncytial virus (RSV)...*28th March, 2008  
Medical/Scientific Affairs, MedImmune Inc., Gaithersburg, MD 20878, USA.- *J Perinatol.* 2008 May;28(5):319-23. Epub 2008 Mar 27. ([DOI Direct Link](#))
  - [Development of molecular and cellular biomarkers of pain.](#)  
*Observation of physiologic and behavioral responses is the main method...*1st March, 2008

## BioNews Results for MedImmune



- [Budesonide/Formoterol Appears Safe, Effective for Asthma Control at 1 Year](#)  
*Medscape: Aug 22 2008 9:15PM Matching: medimmune*
- [Parents don't consider flu vaccines](#)  
*UPI: Aug 22 2008 4:42PM Matching: medimmune*
- [Pharmaceutical Alliance Management](#)  
*Pharma Live: Aug 22 2008 12:04PM Matching: medimmune*
- [MedImmune Initiates First Phase 2 Trial in Lupus Patients With its Antibody Targeting Interferon-alpha](#)  
*Evergreen Investments: Aug 21 2008 10:48PM Matching: medimmune*
- [Survey Shows Parents' Best Intentions Out of Step with Expert Recommendations in Protecting Kids from Flu](#)  
*Macro World Investor: Aug 21 2008 12:05PM Matching: medimmune*
- [Survey Shows Parents' Best Intentions Out of Step with Expert Recommendations in Protecting Kids from Flu](#)  
*Pharma Live: Aug 21 2008 7:49PM Matching: medimmune*
- [Survey Shows Parents' Best Intentions Out of Step with Expert Recommendations in Protecting Kids from Flu](#)  
*Atlanta Business Chronicle: Aug 21 2008 12:25PM Matching: medimmune*
- [Survey Shows Parents' Best Intentions Out of Step with Expert Recommendations in Protecting Kids from Flu](#)  
*Columbus Business First: Aug 21 2008 12:25PM Matching: medimmune*
- [Survey Shows Parents' Best Intentions Out of Step with Expert Recommendations in Protecting Kids from Flu](#)  
*The Business Journal Phoenix: Aug 21 2008 12:19PM Matching: medimmune*
- [Micromet: Another Seal of Approval](#)  
*Yahoo!: Aug 21 2008 6:40AM Matching: medimmune*
- [MedImmune initiates phase 2a trial of lupus drug MEDI-545](#)  
*PharmaBiz: Aug 20 2008 8:39AM Matching: medimmune*
- [AstraZeneca Gives FluMist Spray a Shot in the Arm](#)  
*Seeking Alpha: Aug 19 2008 5:47PM Matching: medimmune*
- [THE AM LAW LITIGATION DAILY: August 18, 2008](#)  
*The American Lawyer: Aug 18 2008 10:38PM Matching: medimmune*
- [Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE](#)  
*KOTA Territory News: Aug 19 2008 2:11AM Matching: medimmune*
- [Medarex Begins Phase II Development Program for Lupus Treatment](#)  
*FDA News: Aug 19 2008 10:27PM Matching: medimmune*



## MedImmune Patents:

- 6692749- [Non-splicing variants of gp350/220](#)
- 6887480- [Streptococcus pneumoniae proteins and vaccines](#)
- 6887699- [Recombinant negative strand RNA virus expression systems and vaccines](#)
- 6908613- [Chimeric human papillomavirus \(HPV\) L1 molecules and uses therefor](#)
- 6913750- [Therapeutic compounds structurally-linked to bacterial polypeptides](#)
- 6955717- [Crystals and structure of Synagis Fab](#)
- 6962701- [Methods of priming the immunogenic activity of vaccines useful for eliciting a protective immune response](#)
- 6962777- [IN VITRO METHOD FOR DISASSEMBLY/REASSEMBLY OF PAPILOMAVIRUS VIRUS-LIKE PARTICLES \(VLPS\), HOMOGENEOUS VLP AND CAPSOMERE COMPOSITIONS PRODUCED BY SAID METHODS; USE THEREOF AS VEHICLE FOR IMPROVED PURIFICATION, AND DELIVERY OF ACTIVE AGENTS](#)
- 6974686- [Recombinant tryptophan mutants of influenza](#)
- 7053072- [Methods for the administration of amifostine and related compounds](#)
- 7083784- [Molecules with extended half-lives, compositions and uses thereof](#)
- 6863893- [Derivatives of choline binding proteins for vaccines](#)
- 6858706- [Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof](#)
- 6855493- [Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment](#)
- 6713296- [VZV gene, mutant VZV and immunogenic compositions](#)
- 6737063- [FimH adhesin proteins and methods of use](#)
- 6753323- [Topical administration of amifostine and related compounds](#)
- 6764685- [Recombinant parainfluenza virus expression systems and vaccines](#)
- 6811784- [Recombinant parainfluenza virus expression system and vaccines](#)
- 6818216- [Anti-RSV antibodies](#)
- 6830748- [Recombinant RSV virus expression systems and vaccines](#)
- 6833356- [Pneumococcal protein homologs and fragments for vaccines](#)
- 6841545- [Stable amorphous amifostine compositions and methods for the preparation of same](#)
- 6843996- [Immunogenic composition comprising an influenza virus with a temperature sensitive PB2 mutation](#)
- 7105575- [Methods for the treatment of neuro- disorders using aminothiols compounds](#)
- 7122194- [Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural motifs](#)
- 7276356- [Recombinant negative strand RNA virus expression systems and vaccines](#)
- 7294336- [Stabilized liquid anti-RSV antibody formulations](#)
- 7297337- [EphA2 T-cell epitopes and uses therefor](#)
- 7309490- [Methods of priming the immunogenic activity of vaccines useful for eliciting a protective immune response](#)
- 7323172- [Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment](#)
- 7341729- [Recombinant parainfluenza virus expression systems and vaccines](#)
- 7351533- [In vitro method for disassembly/reassembly of papillomavirus virus-like particles \(VLPs\). Homogeneous VLP and capsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents](#)
- 7354584- [Recombinant IL-9 antibodies](#)

- 7368440- [Methods for the administration of amifostine and related compounds](#)
- 7371383- [Recombinant anti-interleukin-9 antibodies](#)
- 7262045- [Methods of producing influenza vaccine compositions](#)
- 7258873- [Preservation of bioactive materials by spray drying](#)
- 7238481- [Recombinant parainfluenza virus expression systems and vaccines](#)
- 7132100- [Stabilized liquid anti-RSV antibody formulations](#)
- 7132107- [Streptococcus pneumoniae proteins and vaccines](#)
- 7135180- [Preservation of bioactive materials by freeze dried foam](#)
- 7179900- [Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment](#)
- 7204990- [Attenuation of cytomegalovirus virulence](#)
- 7205013- [Recombinant RSV virus expression systems and vaccines](#)
- 7208162- [Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents](#)
- 7208165- [Human cytomegalovirus DNA sequences](#)
- 7229618- [Crystals and structure of Synagis Fab](#)
- 7229619- [Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment](#)
- 7381425- [Preservation of bioactive materials by freeze dried foam](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's relate service indepth.

The annual cost is \$495.00 for established organizations and \$295.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.  
UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

